Here, we provide evidence for a functional role of artemin (ARTN) in progression of endometrial carcinoma (EC). Increased ARTN protein expression was observed in EC compared with normal endometrial tissue, and ARTN protein expression in EC was significantly associated with higher tumor grade and invasiveness. Forced expression of ARTN in EC cells significantly increased total cell number as a result of enhanced cell cycle progression and cell survival. In addition, forced expression of ARTN significantly enhanced anchorage-independent growth and invasiveness of EC cells. Moreover, forced expression of ARTN increased tumor size in xenograft models and produced highly proliferative, poorly differentiated, and invasive tumors. The ARTN-stimulated increases in oncogenicity and invasion were mediated by increased expression and activity of AKT1. Small interfering RNA-mediated depletion or antibody inhibition of ARTN significantly reduced oncogenicity and invasion of EC cells. Thus, inhibition of ARTN may be considered as a potential therapeutic strategy to retard progression of EC. (Endocrinology 151: 909 -920, 2010) 
Here, we provide evidence for a functional role of artemin (ARTN) in progression of endometrial carcinoma (EC). Increased ARTN protein expression was observed in EC compared with normal endometrial tissue, and ARTN protein expression in EC was significantly associated with higher tumor grade and invasiveness. Forced expression of ARTN in EC cells significantly increased total cell number as a result of enhanced cell cycle progression and cell survival. In addition, forced expression of ARTN significantly enhanced anchorage-independent growth and invasiveness of EC cells. Moreover, forced expression of ARTN increased tumor size in xenograft models and produced highly proliferative, poorly differentiated, and invasive tumors. The ARTN-stimulated increases in oncogenicity and invasion were mediated by increased expression and activity of AKT1. Small interfering RNA-mediated depletion or antibody inhibition of ARTN significantly reduced oncogenicity and invasion of EC cells. Thus, inhibition of ARTN may be considered as a potential therapeutic strategy to retard progression of EC. (Endocrinology 151: 909 -920, 2010) E ndometrial carcinoma (EC) remains the most common genital tract malignancy in women. The majority of cases that present with early stage (stage I/II) disease are cured with surgery and exhibit a favorable prognosis. However, reported median survival times in patients with late stage (stage III/IV) or recurrent disease treated by chemotherapy is rarely more than 1 yr (1). Despite progress in defining mechanisms associated with the development of EC, the molecular pathology of myometrial infiltration/ invasion in EC remains unclear (1, 2) . Clinically, myometrial invasion correlates to more undifferentiated tumors, to lymph vascular invasion, and to node affectation with consequent high risk of recurrence (1) . The characterization of novel oncogenic molecules involved in EC and associated with myometrial invasion, and the development of targeted therapies specifically directed against them, would potentially improve the prognosis of late stage EC.
Artemin (ARTN) is a neurotrophic factor, belonging to the glial cell-derived neurotrophic factor (GDNF) family of ligands (GFLs). Despite low amino acid sequence homology, GFLs and the TGF-␤ superfamily possess similar tertiary conformations and both belong to the cystineknot protein family and function as homodimers (3) . ARTN is postulated to initiate signaling cascades by binding to GDNF family receptor (GFR)␣3 with subsequent GFR␣3 interaction with the tyrosine kinase receptor (RET). RET subsequently activates downstream effectors in the Ras/ERK, phosphatidylinositol 3-kinase (PI3K)/ serine-threonine kinase (AKT), p38/MAPK, and c-Jun Nterminal kinase pathways modulating cell growth, differentiation, migration, and survival (4, 5) . However, the GFR␣ binding specificities are not exclusive. For example, ARTN can also bind to GFR␣1 and GDNF to GFR␣2 and GFR␣3 (6) . Furthermore, GDNF, for example, has been demonstrated to activate cytoplasmic Src family tyrosine kinases via GFR␣1 in RET-deficient cells (7) , indicative that GFLs also function independent of RET.
There are several reports linking GFLs or the signaling pathways they activate to cancer. We have recently demonstrated that high expression of ARTN predicted residual disease after chemotherapy, metastases, relapse, and death in mammary carcinoma (8) . Concordantly, ARTN promoted oncogenicity, tumor growth, and invasion of mammary carcinoma cells (8) . Expression of GDNF and ARTN are also associated with invasion of pancreatic malignant cells along pancreatic nerves (9, 10) . Moreover, elevated levels of GFR␣1 mRNA has been reported in invasive mammary carcinoma and its expression, along with RET, is required for GDNF-dependent progression of estrogen receptor (ER)ϩ mammary carcinomas (11, 12) . Furthermore, mutational deregulation of RET results in multiple endocrine neoplasia type 2A and type 2B, familial medullary thyroid carcinoma, and papillary thyroid carcinoma (13, 14) .
Here, we have defined a functional role for ARTN in EC. Increased expression of ARTN protein was observed in EC compared with normal endometrial (NE) tissue, and higher expression of ARTN protein within EC was significantly associated with higher tumor grade and myometrial invasion. We demonstrated that forced expression of ARTN in EC cells promoted oncogenicity, increased xenograft growth, and increased migration and invasion. Depletion or functional inhibition of ARTN in EC cells reduced oncogenic properties. We therefore provide evidence that ARTN is important in human endometrial neoplastic processes.
Materials and Methods

Cell culture
The human EC cell lines, RL95-2 and AN3, were obtained from the American Type Culture Collection (Rockville, MD) and cultured as per American Type Culture Collection propagation instructions.
Plasmid constructs
Human ARTN transcript variant 4 (GenBank accession no. NM057090) was cloned into the mammalian expression vector pIRESneo3 (Invitrogen, Carlsbad, CA) as previously described (8) . Plasmids expressing a small interfering RNA (siRNA) targeting all four variants of ARTN and a negative control siRNA were constructed in pSilencer 2.1-U6 hygro vector (Ambion, Austin, TX) as previously described (8) .
Generation of stable cell lines
The human EC cell lines were stably transfected with either pIRESneo3 containing the ARTN cDNA (designated as RL95-2-ARTN and AN3-ARTN) or a pSilencer containing a siRNA targeting ARTN (designated as RL95-2-siARTN and AN3-siARTN), using FuGENE 6 (Roche Applied Science, Indianapolis, IN). Control cells lines were transfected with the empty pIRESneo3 vector (designated RL95-2-vector and AN3-vector) and the negative control siRNA plasmid (Ambion) as siRNA control (designated RL95-2-sivector and AN3-sivector). Positive cell clones were selected by antibiotic resistance as previously described (15) . The expression of ARTN in the stable cell lines was determined by RT-PCR and Western blot analysis. EC cells were also stably transfected with nonrelated cDNAs as controls for the stress-response, and no difference in cell behavior was observed compared with the control vector transfected cells.
RT-PCR and quantitative PCR (qPCR)
Total RNA was isolated from cells [cultured in 10% fetal bovine serum (FBS)] using TRIzol Plus RNA Purification system at 1 ml/10 cm 2 according to the manufacturer's (Invitogen) instructions. RNA samples were further treated with DNase I for 30 min at 37 C. Total RNA was converted to cDNA by using SuperScript III First-Strand Synthesis SuperMix for qPCR, according to the manufacturer's (Invitogen) instructions. Platinum PCR SuperMix High-Fidelity kit (Invitrogen) was used for amplification of cDNA, according to manufacturer's (Invitrogen) instructions. The ABI 7700 real-time PCR system (Applied Biosystems, Foster City, CA) was used for analysis. qPCR was performed as previously described (15) . Gene analysis and the sequences of the primers are described in Supplemental Table 1 , published as supplemental data on The Endocrine Society's Journals Online web site at http://endo.endojournals.org.
Immunoblotting and immunofluorescence
Western blot analysis was performed as previously described (8) using the following antibodies: rabbit anti-Akt polyclonal antibody (Cell Signaling Technology, Inc., Beverly, MA), rabbit anti-p-Akt polyclonal antibody (Cell Signaling Technology, Inc.), goat anti-ARTN polyclonal antibody (R&D Systems, Minneapolis, MN), and a monoclonal antibody against ␤-actin (Santa Cruz Biotechnology, Santa Cruz, CA). Immunofluorescent imaging was performed as previously described (16) using tetramethylrhodamine isothiocyanate-phalloidin (Sigma, St. Louis, MO).
Cell death, proliferation, and oncogenicity assays
Apoptosis was determined by using Annexin V-FLUOS staining kit (Roche Applied Science) and Apo-ONE Homogeneous Caspase-3/7 assay kit (Promega, Madison, WI) following manufacturer's instructions. Other biological assays such as total cell number, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, 5-bromo-2-deoxyuridine (BrdU) incorporation, anchorage-independent growth (soft agar, foci formation, and suspension culture), two-dimensional (2D) and threedimensional (3D) morphogenesis, and in vitro cell motility (migration and invasion) assays were performed as previously described (15) . 
EC tissue microarrays and immunohistochemistry (IHC)
Antibody generation and bioassays
Recombinant ARTN protein was expressed and purified in Escherichia coli using glutathione S-transferase tag using the pGEX-4T1-ARTN plasmid as previously described (17) and was used to generate chicken polyclonal antibody. For bioassays, chicken polyclonal anti-ARTN antibody (500 g/ml) and control antibodies (preimmune polyclonal IgY, 500 g/ml) were diluted in PBS buffer. Akt Inhibitor IV was purchased from Calbiochem, Inc. (San Diego, CA).
Xenograft analyses
Tumor xenograft growth was performed essentially as previously described (18) . RL95-2-vector or RL95-2-ARTN cells (1.5 ϫ 10 8 ) were suspended in 100 l PBS and injected sc into 3-to 4-wk-old BALBc nu/nu mice (Shanghai Slaccas Co., Shanghai, China). Histological analyses with hematoxylin and eosin, BrdU, and terminal transferase deoxyuridine triphosphate nick end labeling (TUNEL) immunostaining were performed as previously described (15) . Experiments were performed according to Institutional Animal Care and Use Committee guidelines (available at www.iacuc.org) with local institutional approval.
Statistics
All experiments were performed at least three times. All numerical data are expressed as mean Ϯ SEM from a representative experiment performed in triplicate. Xenograft growth and numerical data are expressed as mean Ϯ SEM from a representative experiment performed in triplicate. Data were analyzed using an unpaired two-tailed t test or ANOVA by GraphPad Prism5.
Results
Increased ARTN expression in EC is significantly associated with higher tumor grade and myometrial invasion
We evaluated ARTN expression in 117 endometrial tissue samples which were sub-classified into NE tissue (n ϭ 38), simple endometrial hyperplasia (SEH) (n ϭ 20), complex endometrial hyperplasia (CEH) (n ϭ 12), and uterine EC (n ϭ 47) using IHC staining. Low intensity of ARTN expression was localized in the cytoplasm of NE epithelial cells (Fig. 1A ). Higher intensity of ARTN expression was observed in diseased endometrial tissue samples ( Fig. 1 , B and C). However, the intensity of ARTN expression was not significantly different between NE, SEH, and CEH. In contrast, EC tissue samples were significantly associated with higher intensity of ARTN expression ( Fig. 1, D and E). ARTN expression was predominately localized in the cytoplasm of tumor cells (Fig.  1D ). Stromal cells and smooth muscle cells of the uterine wall and blood vessels also exhibited variable intensities of ARTN immunoreaction.
We further assessed the correlation between ARTN expression and clinicopathological parameters of EC (Table 1) . ARTN positivity in EC patients was significantly associated with higher International Federation of Gynecology and Obstetrics (FIGO) grade (P ϭ 0.007). FIGO grades 2 and 3 are associated with higher incidence of deep myometrial invasion and lymph node metastases (1). However, there was no significant association observed between ARTN positivity and lymph node metastases in EC, but ARTN positive tumors were significantly (P ϭ 0.021) associated with myometrial invasion.
Forced expression of ARTN stimulates cellular proliferation and oncogenicity of human EC cells
To determine the functional consequences of ARTN expression in EC, we stably transfected two ERϩ EC cell lines (RL95-2 and AN3) with an expression plasmid encoding ARTN (RL95-2-ARTN and AN3-ARTN) and with the empty plasmid as control, respectively. Pooled stably transfected cells were used to minimize any potential effect of clonal selection. Stable transfection of ARTN encoding plasmid in EC cells resulted increased ARTN mRNA as well as increased cellular production of ARTN protein, as demonstrated by semi-quantitative RT-PCR and Western blot analysis, respectively ( Fig. 2A) . RT-PCR analysis demonstrated the expression of GFR␣1-4 and RET in both RL95-2 and AN3 cells (Fig. 2B) .
In monolayer culture, RL95-2-ARTN total cell number increased significantly more than RL95-2-vector cell number over a period of 14 d in serum replete (10% FBS) and serum depleted (0.2% FBS) media (Fig. 2, C and D) . In addition, RL95-2-ARTN cells exhibited significantly enhanced cell viability (RL95-2-vector 100 Ϯ 6.1% vs. RL95-2-ARTN 148.7 Ϯ 6.6%, P Ͻ 0.001) compared with RL95-2-vector cells, as measured by MTT in monolayer culture. Increased cell growth may result from the net outcome of increased cell cycle progression and/or increased cell survival. RL95-2-ARTN cells exhibited significantly increased cell cycle S phase entry determined by BrdU incorporation in the presence of either 10% FBS (60 Ϯ 3.5 vs. 31 Ϯ 4.4%, P Ͻ 0.001) or 0.2% FBS (41 Ϯ 4.5 vs. 25 Ϯ 2%, P Ͻ 0.001), compared with RL95-2-vector cells. RL95-2-ARTN cells also exhibited significantly diminished apoptotic cell death (28 Ϯ 2 vs. 38 Ϯ 2.4%, P Ͻ 0.001) as a consequence of serum deprivation and also reduced caspase-3/7 activity (75 Ϯ 3.7 vs. 100 Ϯ 4%, P Ͻ 0.001) compared with RL95-2-vector cells.
We next used qPCR analysis to examine the effect of forced expression of ARTN on the relative expression levels of genes involved in cell cycle progression and cell survival. Forced expression of ARTN consistently increased the mRNA levels of CCND1, CDK2, and CDC25A required for cell cycle progression (19, 20) and BCL-2 and BCL2L1, anti-apoptotic genes required for cell survival. Additionally, decreased mRNA levels of several proapoptotic genes, including BAD and BAX, were observed in RL95-2 cells consequent to the forced expression of ARTN. Furthermore, forced expression of ARTN in RL95-2 cells increased levels of TERT mRNA indicative of decreased cellular senescence and enhanced cell survival (Table 2 ) (21) . Similar directional changes in expression of genes involved in cell cycle progression and survival were observed in AN3 cells with the forced expression of ARTN (Supplemental Table 2 ). Thus, forced expression of ARTN in EC cells increased cell cycle progression and decreased apoptosis.
Another characteristic of oncogenically transformed cells is the capacity for anchorage-independent cell growth (22, 23) . Forced expression of ARTN in RL95-2 cells significantly enhanced anchorage-independent growth as indicated by colony formation in soft agar (Fig. 2E) , growth in suspension culture (Fig. 2F) , and foci formation (Fig.  2G) . Moreover, individual colony size in soft agar was markedly increased by forced expression of ARTN in RL95-2 cells. Consistent with these observations, forced expression of ARTN in AN3 cells also significantly increased colony formation in soft agar (Fig. 2E) . Therefore, forced expression of ARTN in EC cells increased the capacity for anchorage-independent growth.
In addition, when cells were cultured in 3D Matrigel, the total number of colonies generated by RL95-2-ARTN cells was significantly increased (4780 Ϯ 98 vs. 3281 Ϯ 56, P Ͻ 0.001) compared with RL95-2-vector cells.
Forced expression of ARTN in EC cells promotes a mesenchymal phenotype with increased migration and invasion
During progression of carcinoma, increased invasiveness of tumor cells is often associated with the phenotypic conversion of cells from an epithelial to a mesenchymal morphology, with concomitant changes in gene expression (24) . We observed that forced expression of ARTN in EC cells was associated with altered cell morphology. RL95-2-vector cells exhibited epithelial characteristics and grew as defined grouped colonies with copius cell-to-cell contact (Fig. 3A) similar to the parental RL95-2 cell line (data not shown). However, RL95-2-ARTN cells exhibited mesenchymal characteristics such as an elongated fibroblast-like morphology, loss of cellcell contact, and formation of multiple cellular protrusions (Fig. 3A) . Moreover, RL95-2-vector cells grew as rounded colonies when cultured on 2D Matrigel, whereas RL95-2-ARTN colonies adopted a stellate organization with cords of cells extending from the colonies (Fig. 3B) . Similar morphological changes were observed in AN3 cells with forced expression of ARTN (Fig. 3B ). 3D structures were generated by plating RL95-2-vector and RL95-2-ARTN cells as single cells in Matrigel. RL95-2-vector colonies appeared well-defined with regular spheroid morphology, only 10 Ϯ 2.2% of RL95-2-vector colonies exhibited a nonspheroidal disorganized structure. In contrast, 85 Ϯ 5.2% of RL95-2-ARTN colonies exhibited a disorganized structure of irregular morphology in Matrigel (Fig. 3C) . Similarly, when cultured in 3D Matrigel, only 18 Ϯ 5.2% of AN3-vector colonies exhibited a disorganized structure in comparison with 75 Ϯ 6.2% of AN3-ARTN colonies. RL95-2 cells with forced expression of ARTN also exhibited altered organization of the filamentous actin (f-actin) cytoskeleton. RL95-2-vector cells displayed well-organized cortical rings of f-actin near the cell periphery with regular appearance of stress fibers, similar to the parental RL95-2 cells. In contrast, stress fibers in RL95-2-ARTN cells were less and more diffuse, and accumulation of f-actin at the cell periphery coinciding with the leading edges of the cell was observed (Fig. 3D) . Similar reorganization of the f-actin cytoskeleton was observed in AN3 with the forced expression of ARTN (Fig. 3D) . In accord with morphological changes observed with forced expression of ARTN, qPCR analysis demonstrated increased mRNA levels of the mesenchymal marker, VIMENTIN, in RL95-2-ARTN cells relative to RL95-2-vector cells (Table 2) . VIMENTIN is associated with dissolution of the adherens junction and a highly invasive cellular phenotype (25, 26) . (Table 2) . Similar directional changes in expression of genes involved in invasion and metastasis were observed in AN3 cells with the forced expression of ARTN (supplemental Table  S3 ). Thus, forced expression of ARTN in EC cells promoted a mesenchymal phenotype with increased migration and invasion.
Forced expression of ARTN promotes xenograft growth of human EC cells
In vitro analyses of oncogenic transformation are not always concordant with tumorigenic potential in vivo. Therefore, we implanted both RL95-2-vector and RL95-2-ARTN cells sc into female athymic mice using PBS as a vehicle. Both cell lines formed palpable tumors after less than 1 wk. RL95-2-ARTN tumors grew significantly faster than the RL95-2-vector tumors, resulting in a significantly larger tumor mass after 6 wk (Fig. 4A) . Histological examination revealed that RL95-2-vector cell generated tumors possessed well defined margins with no infiltration to surrounding tissues. However, RL95-2-ARTN cell generated tumors were larger and possessed an ill-defined margin, which blended with surrounding tissues, and appeared highly invasive, infiltrating the underlying skeletal muscle and adipose tissue (Fig. 4B) . In addition, RL95-2-ARTN cells were also observed in blood vessels of the tumor periphery indicative of hematogenous spread of the tumor. Hemorrhage and necrosis was occasionally observed in the center of the RL95-2-ARTN generated tumor mass.
We also determined whether forced expression of ARTN exerted an effect on EC cell proliferation and survival in vivo. RL95-2-ARTN cell generated tumors exhibited significantly in- creased nuclear BrdU incorporation (performed on paraffin-embedded tumor tissue sections) compared with RL95-2-vector cell generated tumors (Fig. 4C) . In addition, TUNEL assay demonstrated that RL95-2-ARTN cell generated tumors contained significantly less apoptotic nuclei than tumors formed by RL95-2-vector cells (Fig. 4D) .
Inhibition of AKT activity significantly diminishes ARTN-stimulated oncogenicity and invasiveness of EC cells
qPCR analyses demonstrated that expression of AKT1 mRNA was increased more than 2-fold by forced expression of ARTN in RL95-2 cells relative to vector control cells ( Table 2 ). The AKT signaling pathway has been reported to promote oncogenicity and invasiveness in human carcinoma cells (27) . We therefore determined the total AKT protein and pAKT levels in RL95-2-vector and RL95-2-ARTN cells Ϯ treatment with Akt Inhibitor IV. Forced expression of ARTN in RL95-2 cells produced increased levels of total AKT and concordantly pAKT as demonstrated using Western blot analysis (Fig. 5A) . Treatment of RL95-2-vector and RL95-2-ARTN cells with Akt Inhibitor IV reduced the levels of pAKT but did not affect the total AKT level. As described previously, forced expression of ARTN in RL95-2 cells significantly enhanced their capacity for anchorage-independent growth and invasion when compared with vector control cells. Upon exposure to Akt Inhibitor IV, both RL95-2-vector and RL95-2-ARTN cells exhibited decreased capacity for anchorage-independent growth and invasion (Fig. 5, B and C) . Treatment with Akt Inhibitor IV reduced the basal capacity for anchorage-independent growth and invasion of RL95-2-vector cells and also eliminated or largely abrogated the stimulatory effects of ARTN on anchorage-independent growth and invasion in RL95-2-ARTN cells. In addition, AN3-ARTN cells exhibited similar increased total AKT and pAKT when compared with vector transfected control cells (Fig. 5) . Akt Inhibitor IV also largely abrogated the ability of ARTN to stimulate anchorage-independent growth and invasion of AN3 cells. Thus, ARTN used Akt signaling to promote oncogenicity and invasiveness of EC cells.
Depletion or functional inhibition of ARTN reduces oncogenicity of EC cells
We next depleted ARTN expression in EC cells by use of siRNA. Reduced expression of ARTN mRNA and protein was demonstrated using semi-quantitative RT-PCR and Western blot analysis, respectively (Fig. 6A) . siRNA mediated depletion of ARTN expression in RL95-2-siARTN cells resulted in significantly decreased total cell number as compared with RL95-2-sivector cells when cultured on monolayer (Fig. 6B) . In addition, depletion of ARTN expression in RL95-2 cells in monolayer culture significantly reduced cell viability (79 Ϯ 1.3 vs. 100 Ϯ 0.8%, P Ͻ 0.001) as determined by MTT assay when compared with RL95-2-sivector cells. Concordantly, RL95-2-siARTN cells exhibited significantly reduced entry to S phase (15 Ϯ 2 vs. 25 Ϯ 3%, P Ͻ 0.001) compared with RL95-2-sivector cells. RL95-2-siARTN cells also exhibited significantly enhanced apoptosis (44 Ϯ 3 vs. 33.3 Ϯ 2%, P Ͻ 0.001) as a consequence of serum deprivation and elevated caspase -3/7 activity (126 Ϯ 2.4 vs. 100 Ϯ 1.57%, P Ͻ 0.001) as compared with RL95-2-sivector cells. Moreover, siRNA mediated depletion of ARTN in RL95-2 and AN3 cells significantly reduced anchorage-independent growth as indicated by reduced colony formation in soft agar (Fig. 6C) . When cultured in 3D Matrigel, RL95-2-siARTN colony number was noticeably reduced (2600 Ϯ 54 vs. 3800 Ϯ 62 colonies, P Ͻ 0.001) compared with RL95-2-sivector colonies. Migration and invasion of RL95-2 and AN3 cells was aslo significantly decreased by depletion of ARTN (Fig. 6D) .
We next generated polyclonal IgY against ARTN protein to functionally antagonize ARTN secreted by EC cells (8) . ARTN IgY antibodies significantly decreased anchorage-independent growth as indicated by decreased colony formation in soft agar and also decreased invasion of RL95-2 cells (Fig. 6, E and F) . Functional inhibition of ARTN in AN3 cells by ARTN IgY also resulted in decreased colony formation in soft agar and decreased cell invasion (Fig. 6, E and F) . Therefore, functional inhibition of ARTN reduced the oncogenic potential of EC cells. 
Discussion
Myometrial infiltration in EC remains a serious cause of recurrence and unfavorable prognosis (28) . It is associated with high proliferation, marked invasion, and angiogenesis (25) . Here, we document that ARTN expression in EC is significantly associated with higher EC tumor grade and myometrial invasion. We have also demonstrated functional concordance with the histopathological data as ARTN expression increased the oncogenic, migratory and invasive capacity of EC cells. That depletion or functional inhibition of ARTN also significantly reduced the oncogenic and invasive properties of EC cells may herald a potential therapeutic option to control late stage EC. ARTN increased EC cell proliferation and survival both in vitro and in tumor xenografts in vivo, associated with increased mRNA levels of regulators of cell proliferation and cell survival. Elevated levels of cell cycle regulators, including CCND1, CDK4, and CDK2, has been reported to correlate with higher proliferation rates in EC (19, 29, 30) . Here, ARTN was observed to increase expression of CCND1 and CDK2 in EC cells. Increased expression of CCND1 and CDK2 in EC is associated with higher histological grade and worse survival outcome in patients (29) . As in mammary carcinoma (8) , ARTN also increased the expression of BCL2 mRNA in EC cells. BCL2 is a potent antiapoptotic molecule, increased expression of which promotes cell survival and contributes to chemotherapeutic resistance (31) . However, BCL2 expression is decreased in atypical hyperplasia and endometrial adenocarcinoma relative to normal endometrium and BCL2 expression in EC is correlated with a favorable prognosis in patients (32, 33) . Other cell survival pathways may therefore be more relevant to ARTN-dependent EC. Increased levels of AKT1 and pAKT were observed consequent to forced expression of ARTN in EC cells. AKT1 is the most highly expressed Akt isoform in the mouse uterus, and deficiency of Akt1 is sufficient to inhibit EC development in mouse models (34) . Loss or deregulation of phosphatase and tensin homolog results in increased AKT expression in human EC cells with resultant increased mammalian target of rapamycin activity providing survival signals to promote development of EC (27) . Accordingly, decreased AKT in advanced human EC is associated with improved patient survival (35) . In vitro a small molecule inhibitor based inhibition of AKT kinase activity also induces apoptosis in human EC cells (36) . Furthermore, down-regulation of AKT (including the AKT2 isoform) restores cisplatin-induced apoptosis in human EC cells resistant to chemotherapy (27, 37) . ARTN therefore regulates gene expression functionally concordant with the development of EC and specifically uses AKT to stimulate oncogenicity and invasion.
We also demonstrated the ARTN stimulated promotion of epitheliomesenchymal transition and cellular invasion in EC cells concordant with ARTN expression being histopathologically correlated with invasion. Accumulating evidence supports the proinvasive effect of GFLs in cancer. For example, GDNF stimulates migration and invasion of PANC-1 (pancreatic carcinoma) cells via RETdependent activation of the p44/42 MAP kinase and PI3K/ AKT pathways (38, 39) . In addition, GDNF was reported to increase the expression of MMP9 in a PI3K-dependent manner in pancreatic carcinoma cells (40) . Similar to GDNF, ARTN was also reported to be involved in spreading of pancreatic carcinoma cell along pancreatic nerves (9, 10) . ARTN has also been reported to stimulate invasion in mammary carcinoma cells and increased expression of ARTN predicts metastatic disease in mammary carcinoma (8) . Here, we observed that forced expression of ARTN increased mRNA levels of invasion and metastasis promoting genes, such as MMP1, MMP9, and PAI-1/SERPINE1. MMP1 expression is increased in endometriosis relative to normal endometrium cells and associated with invasion of cells to surrounding tissues (41) . Higher expression of MMP9 in endometrial cancer and has been reported to be associated with invasive and aggressive behavior of uterine serous carcinomas (42) . Moreover, elevated levels of PAI-1/SERPINE1 in EC are associated with higher tumor grade and low survival (43) . Concurrently, forced expression of ARTN increased mRNA levels of TWIST, a transcription factor, which is up-regulated in EC, as well as significantly associated with myometrial infiltration and predicts worse survival outcome (44) . VIMENTIN is one marker gene for epitheliomesenchymal transition (45) , and mRNA levels of VIMENTIN were increased with forced expression of ARTN in EC cells. In vitro, increased expression of VIMENTIN in EC cells is associated with dissolution of the adherens junction (25) . However, elevated expression of VIMENTIN observed in EC is correlated with factors indicating a favorable prognosis, such as low tumor grade, and presence of ER/progesterone receptor expression (46) .
We evaluated the therapeutic potential of inhibition of ARTN by determining the effects of functional inhibition in EC cells. ARTN was expressed 83% of EC examined here, a high percentage compared with other targeted molecules which are currently being investigated as therapeutic targets in EC, such as mammalian target of rapamycin, HER2/neu, epidermal growth factor receptor, and vascular endothelial growth factor (28) . For example, HER2/ neu is overexpressed in 20 -30% of reported cases of EC (47) . Interestingly, treatment with Trastuzumab (a monoclonal antibody directed against HER-2/neu) showed minimal clinical benefit when used in advanced and recurrent or persistent EC (47) . In vitro studies demonstrated that estradiol counteracted the inhibitory effects of Trastuzumab by rapid phosphorylation of ERK-1/2, a kinase downstream of the HER2/neu receptor in EC cells, which may explain lack of a significant clinical response (48) . In any case, as with other human neoplastic disorders, combined therapy will be more effective than single agents, and antiestrogen combinations with Trastuzumab may provide a more effective therapy for ER and HER2/neu positive EC (48) . We note that antibody-mediated functional inhibition of ARTN exerted marked single agent effects on oncogenic functions of EC cells, in contrast to Trastuzumab which exerted no effect in the absence of exogenously added heregulin in EC cell lines (48) . Similarly, in HER/neu positive mammary carcinoma cells (49) , Trastuzumab exerts little single agent effect in comparison with antibody-mediated inhibition of ARTN (8) . We do note that we used polyclonal antibody inhibition of ARTN, which may potentially be more effective than inhibition with a monoclonal antibody such as Trastuzumab. In any case, the marked single agent effects of functional inhibition of ARTN warrants the development of function inhibiting monoclonal antibodies to ARTN. Functional inhibition of ARTN with antibodies could also be combined with other targeted agents such as antiestrogens to obtain additive or synergistic effects in EC. Such approaches are currently under investigation.
In conclusion, higher expression of ARTN in EC was associated with increased invasiveness and higher tumor grade. Forced expression of ARTN in EC cells increased oncogenicity and invasion. Concordantly, the oncogenicity of EC cells was significantly reduced by depletion or functional inhibition of ARTN. These findings warrant consideration be given to development of function inhibiting antibodies to ARTN to be used as a therapeutic agent in invasive or metastatic EC.
